Announces Appointment of New Chief Executive Officer

August 12, 2024 07:45 ET

Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FRA: PSH), a clinical-stage biotechnology company specializing in regenerative medicine cell therapies, announced the appointment of Mr. Brett Whalen as its new Chair.

Mr. Jonathan Rigby as the Company's New Chief Executive Officer

Effective September 5, 2023, Mr. Rigby will succeed Dr. Philip Toleikis, who will remain with Sernova in an advisory role. Mr. Whalen, a seasoned biotechnology executive, brings more than 25 years of leadership experience to Sernova, including roles at Genzyme, Biogen, and Cytokinetics.

In conclusion, these appointments mark a significant milestone in Sernova's journey, as the company strengthens its leadership team to drive its mission of developing innovative cell therapies for patients with chronic diseases.